<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777595</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0808-PR-0036</org_study_id>
    <nct_id>NCT00777595</nct_id>
  </id_info>
  <brief_title>Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers</brief_title>
  <acronym>CT14</acronym>
  <official_title>A Randomized, Double Blind, Single Dose, Positive and Placebo Controlled, Crossover Study of the Effects of Inhaled Carmoterol, at the Proposed Therapeutic and Supratherapeutic Doses, on the QTc Intervals in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of single doses of therapeutic and&#xD;
      supratherapeutic doses of inhaled CHF 4226 pMDI on ventricular repolarization in healthy&#xD;
      subjects compared with placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary purposes of this study are to 1) determine if there is a relationship between&#xD;
      the duration of the QTc intervals and the plasma concentrations of carmoterol; 2) expand the&#xD;
      available information on plasma pharmacokinetics and urine excretion for inhaled carmoterol&#xD;
      at the proposed therapeutic and supra-therapeutic doses; and 3) generate additional safety&#xD;
      information.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTci</measure>
    <time_frame>ECGs taken every treatment period on day -1 and day +1 at -1, -0.5, -0.25, 0.08, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTcX interval (subject-specific correction of QTcF, QTcB and QTcH)</measure>
    <time_frame>ECGs taken every treatment period on day -1 and day +1 at -1, -0.5, -0.25, 0.08, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration (AUC, Cmax, Tmax)</measure>
    <time_frame>Each treatment period on dosing day at -0.75, 0.08, 0.25, 0.5, 1, 2, 4, 6, 8 and 12 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion (Ae)</measure>
    <time_frame>Each treatment period on day of dosing at -0.75, 0.58 and 24 hours.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single therapeutic dose of CHF 4226 pMDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single supratherapeutic dose of CHF 4226 pMDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of moxifloxacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 4226 pMDI</intervention_name>
    <description>Inhaled solution, single therapeutic dose</description>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>Carmoterol HFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 4226 pMDI</intervention_name>
    <description>Inhaled solution, single supratherapeutic dose</description>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Carmoterol HFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled solution, single dose of placebo</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Tablet, oral, 400mg, single dose</description>
    <arm_group_label>Treatment D</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult male or female subjects, 18-55 years of age who provided written&#xD;
             informed consent.&#xD;
&#xD;
          -  A body mass index (BMI) between 18 - 30, inclusive.&#xD;
&#xD;
          -  A normal blood pressure (&lt; 140mmHg systolic and &lt; 90mmHg diastolic)&#xD;
&#xD;
          -  A normal 12-lead ECG (QTcF interval &lt; 450msec for males and &lt; 470msec for females).&#xD;
&#xD;
          -  A serum potassium &lt;/= 4.0mEq/L.&#xD;
&#xD;
          -  A calculated creatinine clearance &gt; 80mL/min.&#xD;
&#xD;
          -  Male subjects must agree to use a medically acceptable contraceptive (abstain from&#xD;
             sexual intercourse, or use a condom with spermicide), have had a vasectomy at least 6&#xD;
             months prior to study participation or have a partner who is not of childbearing&#xD;
             potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or&#xD;
             psychiatric disease.&#xD;
&#xD;
          -  A history of sensitivity or allergy to the quinolone class of antibiotics and/or a&#xD;
             beta 2 adrenergic receptor agonist.&#xD;
&#xD;
          -  Clinically significant screening results (laboratory profiles, medical histories,&#xD;
             ECGs, physical exam).&#xD;
&#xD;
          -  Hemoglobin below the normal reference range for the testing laboratory.&#xD;
&#xD;
          -  Abuse of alcohol or other substances.&#xD;
&#xD;
          -  Current use of tobacco products.&#xD;
&#xD;
          -  Subjects with a positive laboratory test result for hepatitis B, hepatitis C, HIV,&#xD;
             controlled substances, cotinine or alcohol.&#xD;
&#xD;
          -  Any prescription medication taken within 14 days (or 5 elimination half-lives,&#xD;
             whichever is longer) of Study Day -2, or have taken any over-the-counter medications,&#xD;
             including topical medications, vitamins, herbal or dietary supplements/remedies (e.g.,&#xD;
             Saint John's Wort or Milk Thistle), within 14 days of Study Day -2, or planned&#xD;
             concomitant medication while in the study (except for acetaminophen up to 2g/day),&#xD;
             with the exception of hormonal birth control medications or hormone replacement&#xD;
             therapy for females.&#xD;
&#xD;
          -  A history of additional risk factors for Torsade de Pointes (e.g., hypokalemia,&#xD;
             history of drowning survival, family history of Long QT Syndrome, family history of&#xD;
             Short QT Syndrome, or family history of unexplainable early sudden death).&#xD;
&#xD;
          -  Subject is pregnant or lactating female, or female at risk of pregnancy (i.e., not&#xD;
             using an adequate contraceptive method: surgical sterilization [e.g., bilateral tubal&#xD;
             ligation], hormonal contraception [implantable, patch, oral], IUD, and double-barrier&#xD;
             methods [any double combination of: male or female condom with spermicidal gel,&#xD;
             diaphragm, sponge, cervical dap]_.&#xD;
&#xD;
          -  Participation in a study of an investigational drug within 30 days prior to the&#xD;
             baseline ECG.&#xD;
&#xD;
          -  Any condition that, in the judgment of the Investigator, would place a subject at&#xD;
             undue risk, or potentially compromise the results or interpretation of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert I. Cooper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute, Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven E. Linberg, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Chiesi Farmaceutici S.p.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Russell T, Riley SP, Cook JA, Lalonde RL. A perspective on the use of concentration-QT modeling in drug development. J Clin Pharmacol. 2008 Jan;48(1):9-12.</citation>
    <PMID>18094215</PMID>
  </reference>
  <reference>
    <citation>Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Torn√∏e CW, Wang Y, Zhu H, Gobburu JV. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008 Jan;48(1):13-8. Review.</citation>
    <PMID>18094216</PMID>
  </reference>
  <reference>
    <citation>Bloomfield D, Krishna R. Commentary on the clinical relevance of concentration/QTc relationships for new drug candidates. J Clin Pharmacol. 2008 Jan;48(1):6-8.</citation>
    <PMID>18094214</PMID>
  </reference>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>October 20, 2008</study_first_submitted>
  <study_first_submitted_qc>October 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <last_update_submitted>March 26, 2009</last_update_submitted>
  <last_update_submitted_qc>March 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Steven E. Linberg, Ph.D.</name_title>
    <organization>Chiesi Pharmaceuticals Inc.</organization>
  </responsible_party>
  <keyword>QTc</keyword>
  <keyword>CHF 4226 HFA</keyword>
  <keyword>pMDI</keyword>
  <keyword>Carmoterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

